Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Skye Bioscience Inc (OP: SKYE )

N/A UNCHANGED
Last Price Updated: 3:57 PM EDT, Apr 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 12.81
Today's Range N/A - N/A
52wk Range 1.440 - 19.41
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Skye Bioscience Announces $40 Million Private Placement Equity Financing
San Diego, California--(Newsfile Corp. - March 11, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) (the Company), a clinical stage biotechnology... 
Via Newsfile
Skye Bioscience to Present at Oppenheimer Investor Conference
San Diego, California--(Newsfile Corp. - February 7, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a clinical-stage biotechnology company focused... 
Via Newsfile

Performance

More News

Read More
Skye Bioscience And 2 Other Penny Stocks Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing
Via Newsfile
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease
Via Newsfile
Skye Bioscience and Tautomer Bioscience Enter Exclusive License for SBI-100 for Development and Sale of Products for Chronic Pain and Other Indications in South Africa and Rest of Africa
Via Newsfile
Topics Cannabis Intellectual Property
Exposures Cannabis Intellectual Property
Skye Bioscience to Present at BTIG Ophthalmology Day and OIS XIII Ophthalmology Innovation Summit
Via Newsfile
Skye Bioscience Announces Positive Phase 1 Trial Results for SBI-100 Ophthalmic Emulsion, Its First-in-Class CB1 Agonist Being Developed for the Treatment of Glaucoma
Via Newsfile
CORRECTION: Skye Bioscience to Host Virtual Investor Day on October 25, 2023: "CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System"
Via Newsfile
Skye Bioscience to Present at H.C. Wainwright 25th Annual Global Investment Conference
Via Newsfile
Marijuana Stock Movers For August 23, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabis Stock Gainers And Losers From August 25, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Skye Secures $17M And Acquires Novel Phase 2-Ready Cannabinoid 1 Receptor Inhibitor
Via Benzinga
Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody
Via Newsfile
Cannabis Stock Gainers And Losers From August 24, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabis Stock Movers For August 18, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Marijuana Stock Movers For August 22, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Skye Bioscience to Present at H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
Via Newsfile
Bearish Monday For Marijuana Stocks - EVIO, Item 9 Labs Among Top Gainers
Via Benzinga
Bearish Sentiment Across The Cannabis Space - Check Full Movers For August 21, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Bullish Thursday For Marijuana Stocks - EVIO, Tetra Bio Pharma Among Top Gainers
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabis Stock Gainers And Losers From August 16, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabis Stock Gainers And Losers From August 14, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannabis Stock Gainers And Losers From August 11, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Marijuana Stock Movers For August 8, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Diversified Communications
© 2024 Diversified Communications. All rights reserved.